- Mallinckrodt has acquired DM Graham Laboratories of New York, USA. Terms of the agreement were not disclosed. Graham Laboratories, a privately-held contract manufacturer of tablet and capsule dosage pharmaceuticals, will become part of Mallinckrodt's Pharmaceutical Specialities Division. Graham is also licensed to produce medicinal narcotic substances. According to the president, Michael Collins, plans are in place to update and expand the Graham facilities, which will also make several Mallinckrodt products currently in development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze